Non-Small Cell Lung Cancer (NSCLC) Global Market Opportunities And Strategies To 2034
상품코드:1880709
리서치사:The Business Research Company
발행일:2025년 11월
페이지 정보:영문 121 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 비소세포폐암(NSCLC) 시장은 2024년에 약 381억 9,905만 달러의 규모에 이르렀으며, 2019년 이후 7.68%의 연평균 복합 성장률(CAGR)로 성장해 왔습니다. 본 시장은 2024년 381억 9,905만 달러에서 2029년에는 637억 897만 달러로 성장할 전망이며, 10.77%의 성장률로 확대될 것으로 예측되고 있습니다. 그 후 2029년 이후에도 CAGR 10.55%로 성장을 계속해 2034년에는 1,052억 616만 달러에 달할 것으로 예측되고 있습니다.
비소세포폐암(NSCLC)이란 소세포폐암과는 다른 성질을 나타내며 치료에 대한 반응도 다른 폐암의 총칭입니다. 선암, 편평상피암, 대세포암 등 일부 조직학적 아형이 포함됩니다. NSCLC는 일반적으로 소세포폐암(SCLC)보다 성장과 전이 속도가 느린 경향이 있습니다.
비소세포폐암(NSCLC) 시장은 NSCLC 환자를 대상으로 한 치료제, 진단제, 치료 서비스를 개발 및 제공하는 사업체에 의해 만들어지는 수익으로 구성되어 있습니다. 이러한 서비스 및 제품은 주로 병원, 암 전문센터, 외래 종양 클리닉, 때로는 가정 의료 환경에서 사용됩니다.
흡연율 및 대기오염 증가
흡연율 및 대기오염 증가는 과거에 비소세포폐암(NSCLC) 시장의 성장을 가속했습니다. 흡연율 및 대기오염 증가는 비소세포폐암의 발생률 상승으로 이어져, 이것이 효과적인 진단법 및 치료법에 대한 수요를 촉진했습니다. 예를 들어 2024년 5월에 폐 건강 개선 및 폐 질환 예방을 통해 생명을 구하는 활동을 하는 단체 '미국폐협회'가 발표한 데이터에 따르면 하루 15개 미만의 흡연자 비율은 32%에서 58%로 85% 증가했습니다. 또한 미국 환경보호청(미국 정부 기관)에 따르면 2025년 5월 현재 2023년 미국에서는 약 6,600만 톤의 오염물질이 대기 중으로 배출되었습니다. 따라서, 개수 및 개축 활동 증가가 비소세포폐암(NSCLC) 시장의 성장을 가속했습니다.
브로모도메인 억제제, 내성 비소세포폐암 치료로 신속 심사 지정 취득
비소세포폐암(NSCLC) 시장의 기업은 암 유전자 발현을 촉진하는 후성유전자를 억제하는 브로모도메인 억제제를 개발하고 있어 이로써 종양의 성장을 저지하고 치료 저항성을 역전시킬 수 있습니다. 예를 들어, 2025년 8월 스위스에 본사를 둔 생명공학 기업 TOLREMO Therapeutics AG는 주력후보약인 TT125-802가 표적요법 후 진행을 수반하는 상피성장인자 수용체 변이 및 Kirsten 래트육종 바이러스암 유전자 동족체 G12C 변이를 가지는 비소세포폐암의 치료에 있어서 미국 식품의약국(FDA)으로부터 2개의 패스트트랙 지정을 취득했다고 발표했습니다. 경구 약물인 환형 AMP 반응 요소 결합 단백질/p300 억제제 TT125-802는 1상 시험에서 혈소판 감소증을 동반하지 않는 지속적인 단일 요법으로 인한 효과를 포함하여 유망한 효능과 안전성을 나타냈습니다. 이러한 명세는 비소세포 폐암에서 약물 내성을 다루는 차별화된 치료법으로서 TT125-802의 개발을 가속화하는 것입니다.
세계의 비소세포폐암(NSCLC) 시장은 대기업이 진입하는 고도로 집중된 시장입니다. 2024년 기준에서 시장 상위 10개 경쟁업체가 시장 전체의 76.71%를 차지하고 있습니다.
목차
제1장 주요 요약
비소세포폐암(NSCLC) : 시장 매력 및 거시경제 환경
제2장 목차
제3장 표 일람
제4장 그림 일람
제5장 보고서 구성
제6장 시장 특징
일반적인 시장 정의
개요
비소세포 폐암(NSCLC) 시장 정의 및 세분화
시장 세분화 : 유형별
편평상피암
대세포암
선암
기타 유형
시장 세분화 : 치료법별
방사선요법
화학요법
표적요법
면역요법
기타 치료법
시장 세분화 : 유통 채널별
병원 약국
온라인 약국
기타 유통 채널
제7장 주요 시장 동향
브로모도메인 억제제, 내성 비소세포폐암에 대한 신속 심사 지정 취득
이중 면역 활성화 요법이 면역요법 저항성 NSCLC에서 유망한 결과 확인
정밀 NSCLC 치료를 위한 신속한 24시간 종양 프로파일링
경구 티로신 키나아제 억제제가 표적 NSCLC 치료의 진보 가속
FDA가 mRNA 기반 정밀 면역요법의 임상시험 승인
제3세대 EGFR-TKI가 스테이지 III 비소세포 폐암 유지 요법으로서 승인 취득
제8장 세계의 비소세포 폐암(NSCLC) 성장 분석 및 전략적 분석 프레임워크
세계의 비소세포폐암(NSCLC) PESTEL 분석
정치적
경제적
소셜
기술적
환경 요인
법적
최종 사용자(B2B) 분석
병원
전문 클리닉
재택 치료
연구기관
기타 최종 사용자
세계의 비소세포폐암(NSCLC) 시장 : 성장률 분석
시장 성장 실적(2019-2024년)
시장 성장 촉진요인(2019-2024년)
시장 성장 억제요인(2019-2024년)
시장 성장 예측(2024-2029년, 2034년)
예측 성장 요인
정량적 성장 요인
성장 촉진요인
성장 억제요인
세계의 비소세포 폐암(NSCLC) : 총 잠재 시장 규모(TAM)
제9장 세계의 비소세포폐암(NSCLC) 시장 : 세분화
세계의 비소세포폐암(NSCLC) 시장 : 유형별 분석 및 예측(2019-2024년, 2029년, 2034년)
세계의 비소세포폐암(NSCLC) 시장 : 치료법별 분석 및 예측(2019-2024년, 2029년, 2034년)
세계의 비소세포폐암(NSCLC) 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2029년, 2034년)
세계의 비소세포폐암(NSCLC) 시장 : 편평상피암 유형별 세분화 분석 및 예측(2019-2024년, 2029년, 2034년)
세계의 비소세포폐암(NSCLC) 시장 : 대세포암 유형별 세분화 분석 및 예측(2019-2024년, 2029년, 2034년)
세계의 비소세포폐암(NSCLC) 시장 : 선암 유형별 세분화 분석 및 예측(2019-2024년, 2029년, 2034년)
세계의 비소세포폐암(NSCLC) 시장 : 기타 유형 유형별 세분화 분석 및 예측(2019-2024년, 2029년, 2034년)
제10장 비소세포폐암(NSCLC) 시장 : 지역 및 국가별 분석
세계의 비소세포폐암(NSCLC) 시장 : 지역별 분석 및 예측(2019-2024년, 2029년, 2034년)
세계의 비소세포폐암(NSCLC) 시장 : 국가별 분석 및 예측(2019-2024년, 2029년, 2034년)
제11장 아시아태평양 시장
제12장 서유럽 시장
제13장 동유럽 시장
제14장 북미 시장
제15장 남미 시장
제16장 중동 시장
제17장 아프리카 시장
제18장 경쟁 구도 및 기업 프로파일
기업 프로파일
Merck & Co., Inc
AstraZeneca plc
Bristol Myers Squibb Company
F. Hoffman-La Roche Ltd
Pfizer Inc
제19장 기타 주요 기업 및 혁신 기업
Eli Lilly and Company
Regeneron Pharmaceuticals Inc.
Amgen Inc.
Novartis AG
Takeda Pharmaceutical Company Limited
Janssen Biotech, Inc.
Rigel Pharmaceuticals, Inc.
Partner Therapeutics/Merus NV
AbbVie Inc.
Nuvation Bio
Iovance Biotherapeutics
Dizal Pharmaceutical
Daiichi Sankyo/AZ
Xcovery Holdings, Inc.
Boehringer Ingelheim
제20장 경쟁 벤치마킹
제21장 경쟁 대시보드
제22장 주요 인수합병(M&A)
Bristol Myers Squibb, 48억 달러 규모의 Mirati Therapeutics 인수로 종양학 분야 진출 확대
Pierre Fabre 새로운 비소세포폐암 치료 파이프라인 개발을 위해 Vertical Bio 인수
Bristol Myers Squibb 41억 달러 규모의 Turning Point Therapeutics 인수로 정밀 종양학 확장
제23장 최근 동향 : 비소세포 폐암(NSCLC) 시장
제24장 기회와 전략
세계의 비소세포폐암(NSCLC) 시장(2029년) : 새로운 기회를 제공하는 국가
세계의 비소세포폐암(NSCLC) 시장(2029년) : 새로운 기회를 제공하는 부문
세계의 비소세포폐암(NSCLC) 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제25장 비소세포폐암(NSCLC) 시장 : 결론 및 제안
결론
권고
제품
장소
가격
프로모션
사람들
제26장 부록
AJY
영문 목차
영문목차
Non-small cell lung cancer (NSCLC) refers to a group of lung cancers that behave and respond to treatment differently than small cell lung cancer. It includes several histological subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC typically grows and spreads more slowly than small cell lung cancer (SCLC).
The non-small cell lung cancer (NSCLC) market consists of revenues generated by entities that develop and provide therapeutics, diagnostics, and treatment services targeted at NSCLC patients. These services and products are used primarily in hospital settings, cancer specialty centers, outpatient oncology clinics, and sometimes in home care environments.
The global non-small cell lung cancer (NSCLC) market reached a value of nearly $38,199.05 million in 2024, having grown at a compound annual growth rate (CAGR) of 7.68% since 2019. The market is expected to grow from $38,199.05 million in 2024 to $63,708.97 million in 2029 at a rate of 10.77%. The market is then expected to grow at a CAGR of 10.55% from 2029 and reach $105,206.16 million in 2034.
Rising Prevalence Of Smoking And Air Pollution
Rising prevalence of smoking and air pollution propelled the growth of the non-small cell lung cancer (NSCLC) market during the historic period. The increasing prevalence of smoking and air pollution led to a higher incidence of non-small cell lung cancer, which in turn drove demand for effective diagnostics and treatments. For instance, in May 2024, according to American Lung Association, an organization working to save lives by improving lung health and preventing lung disease, the proportion of people smoking fewer than 15 cigarettes a day increased 85% from 32% to 58%. Moreover, in May 2025, according to the United States Environmental Protection Agency, a US-based government agency, in 2023, about 66 million tons of pollutants were emitted into the atmosphere in the United States. Therefore, growing renovation and remodeling activities propelled the growth of the non-small cell lung cancer (NSCLC) market.
Bromodomain Inhibitor Gains Fast Track Designations for Resistant Non-Small Cell Lung Cancer
Companies in the non-small cell lung cancer (NSCLC) market are developing bromodomain inhibitors to block epigenetic readers that drive oncogene expression, thereby halting tumor growth and reversing therapy resistance. For instance, in August 2025, TOLREMO Therapeutics AG, a Switzerland-based biotech company, announces that its lead candidate, TT125-802, receives two Fast Track designations from the United States Food and Drug Administration for the treatment of non-small cell lung cancer with epidermal growth factor receptor mutations and kirsten rat sarcoma viral oncogene homolog G12C mutations after progression on targeted therapies. TT125-802, an oral cyclic AMP response element binding protein binding protein/p300 inhibitor, shows encouraging efficacy and safety in Phase 1 trials, including durable monotherapy responses without thrombocytopenia. These designations support accelerated development of TT125-802 as a differentiated therapy to address drug resistance in non-small cell lung cancer.
The global non-small cell lung cancer (NSCLC) market is highly concentrated, with large players operating in the market. The top 10 competitors in the market made up 76.71% of the total market in 2024.
Non-Small Cell Lung Cancer (NSCLC) Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global non-small cell lung cancer (NSCLC) market as it emerges from the COVID-19 shut down.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for non-small cell lung cancer (NSCLC)? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The non-small cell lung cancer (NSCLC) market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider non-small cell lung cancer (NSCLC) market; and compares it with other markets.
The report covers the following chapters
Introduction and Market Characteristics: - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by therapy and distribution channel.
Key Trends: - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Growth Analysis And Strategic Analysis:- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
Global Market Size And Growth: Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
Regional And Country Analysis: - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
Market Segmentation: - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by therapy and distribution channel and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
Regional Market Size And Growth: - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape: - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Other Major And Innovative Companies:- Details on the company profiles of other major and innovative companies in the market.
Competitive Benchmarking: - Briefs on the financials comparison between major players in the market.
Competitive Dashboard: - Briefs on competitive dashboard of major players.
Key Mergers and Acquisitions: - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
Recent Developments:- Information on recent developments in the market covered in the report.
Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for non-small cell lung cancer (NSCLC) providers in terms of product/service offerings geographic expansion, marketing strategies and target groups
Appendix:- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Type: Squamous Cell Carcinoma; Large Cell Carcinoma; Adenocarcinoma; Other Types
2) By Therapy: Radiation Therapy; Chemotherapy; Targeted Therapy; Immunotherapy; Other Therapies
3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Other Distribution Channels
Companies Mentioned: Merck & Co., Inc.; AstraZeneca; Bristol-Myers Squibb Company; F. Hoffmann-La Roche AG; Pfizer Inc.
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; non-small cell lung cancer (NSCLC) indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1 Executive Summary
1.1 Non-Small Cell Lung Cancer (NSCLC) - Market Attractiveness And Macro Economic Landscape
2 Table Of Contents
3 List Of Tables
4 List Of Figures
5 Report Structure
6 Market Characteristics
6.1 General Market Definition
6.2 Summary
6.3 Non-Small Cell Lung Cancer (NSCLC) Market Definition And Segmentations
6.4 Market Segmentation By Type
6.4.1 Squamous Cell Carcinoma
6.4.2 Large Cell Carcinoma
6.4.3 Adenocarcinoma
6.4.4 Other Types
6.5 Market Segmentation By Therapy
6.5.1 Radiation Therapy
6.5.2 Chemotherapy
6.5.3 Targeted therapy
6.5.4 Immunotherapy
6.5.5 Other Therapies
6.6 Market Segmentation By Distribution Channel
6.6.1 Hospital Pharmacy
6.6.2 Online Pharmacy
6.6.3 Other Distribution Channels
7 Major Market Trends
7.1 Bromodomain Inhibitor Gains Fast Track Designations for Resistant Non-Small Cell Lung Cancer
7.2 Dual-Immune Activation Therapy Shows Promise in Immunotherapy-Resistant NSCLC
7.3 Rapid 24-Hour Tumor Profiling for Precision NSCLC Treatment
8.7 Global Non-Small Cell Lung Cancer (NSCLC) Total Addressable Market (TAM)
9 Global Non-Small Cell Lung Cancer (NSCLC) Market Segmentation
9.1 Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.2 Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.3 Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.4 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Squamous Cell Carcinoma, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.5 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Large Cell Carcinoma, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.6 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.7 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Other Types, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
10 Non-Small Cell Lung Cancer (NSCLC) Market, Regional and Country Analysis
10.1 Global Non-Small Cell Lung Cancer (NSCLC) Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
10.2 Global Non-Small Cell Lung Cancer (NSCLC) Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11 Asia-Pacific Market
11.1 Summary
11.2 Market Overview
11.2.1 Region Information
11.2.2 Market Information
11.2.3 Background Information
11.2.4 Government Initiatives
11.2.5 Regulations
11.2.6 Regulatory Bodies
11.2.7 Major Associations
11.2.8 Taxes Levied
11.2.9 Corporate Tax Structure
11.2.10 Investments
11.2.11 Major Companies
11.3 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.4 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.5 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.6 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market: Country Analysis
11.7 China Market
11.8 Summary
11.9 Market Overview
11.9.1 Country Information
11.9.2 Market Information
11.9.3 Background Information
11.9.4 Government Initiatives
11.9.5 Regulations
11.9.6 Regulatory Bodies
11.9.7 Major Associations
11.9.8 Taxes Levied
11.9.9 Corporate Tax Structure
11.9.10 Investments
11.9.11 Major Companies
11.10 China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.11 China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.12 China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.13 India Market
11.14 India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.15 India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.16 India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.17 Japan Market
11.18 Summary
11.19 Market Overview
11.19.1 Country Information
11.19.2 Market Information
11.19.3 Background Information
11.19.4 Government Initiatives
11.19.5 Regulations
11.19.6 Regulatory Bodies
11.19.7 Major Associations
11.19.8 Taxes Levied
11.19.9 Corporate Tax Structure
11.19.10 Investments
11.19.11 Major Companies
11.20 Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.21 Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.22 Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.23 South Korea Market
11.24 Summary
11.25 Market Overview
11.25.1 Country Information
11.25.2 Market Information
11.25.3 Background Information
11.25.4 Government Initiatives
11.25.5 Regulations
11.25.6 Regulatory Bodies
11.25.7 Major Associations
11.25.8 Taxes Levied
11.25.9 Corporate Tax Structure
11.25.10 Investments
11.25.11 Major Companies
11.26 South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.27 South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.28 South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.29 Australia Market
11.30 Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.31 Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.32 Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.33 Indonesia Market
11.34 Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.35 Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.36 Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12 Western Europe Market
12.1 Summary
12.2 Market Overview
12.2.1 Region Information
12.2.2 Market Information
12.2.3 Background Information
12.2.4 Government Initiatives
12.2.5 Regulations
12.2.6 Regulatory Bodies
12.2.7 Major Associations
12.2.8 Taxes Levied
12.2.9 Corporate tax structure
12.2.10 Investments
12.2.11 Major Companies
12.3 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.4 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.5 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.6 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market: Country Analysis
12.7 UK Market
12.8 UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.9 UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.10 UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.11 Germany Market
12.12 Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.13 Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.14 Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.15 France Market
12.16 France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.17 France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.18 France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.19 Italy Market
12.20 Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.21 Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.22 Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.23 Spain Market
12.24 Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.25 Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.26 Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13 Eastern Europe Market
13.1 Summary
13.2 Market Overview
13.2.1 Region Information
13.2.2 Market Information
13.2.3 Background Information
13.2.4 Government Initiatives
13.2.5 Regulations
13.2.6 Regulatory Bodies
13.2.7 Major Associations
13.2.8 Taxes Levied
13.2.9 Corporate Tax Structure
13.2.10 Major companies
13.3 Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.4 Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.5 Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.6 Russia Market
13.7 Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.8 Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.9 Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14 North America Market
14.1 Summary
14.2 Market Overview
14.2.1 Region Information
14.2.2 Market Information
14.2.3 Background Information
14.2.4 Government Initiatives
14.2.5 Regulations
14.2.6 Regulatory Bodies
14.2.7 Major Associations
14.2.8 Taxes Levied
14.2.9 Corporate Tax Structure
14.2.10 Investments
14.2.11 Major Companies
14.3 North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.4 North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.5 North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.6 North America Non-Small Cell Lung Cancer (NSCLC) Market: Country Analysis
14.7 USA Market
14.8 Summary
14.9 Market Overview
14.9.1 Country Information
14.9.2 Market Information
14.9.3 Background Information
14.9.4 Government Initiatives
14.9.5 Regulations
14.9.6 Regulatory Bodies
14.9.7 Major Associations
14.9.8 Taxes Levied
14.9.9 Corporate Tax Structure
14.9.10 Investments
14.9.11 Major Companies
14.10 USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.11 USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.12 USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.13 Canada Market
14.14 Summary
14.15 Market Overview
14.15.1 Country Information
14.15.2 Market Information
14.15.3 Background Information
14.15.4 Government Initiatives
14.15.5 Regulations
14.15.6 Regulatory Bodies
14.15.7 Major Associations
14.15.8 Taxes Levied
14.15.9 Corporate Tax Structure
14.15.10 Investments
14.15.11 Major Companies
14.16 Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.17 Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.18 Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15 South America Market
15.1 Summary
15.2 Market Overview
15.2.1 Region Information
15.2.2 Market Information
15.2.3 Background Information
15.2.4 Government Initiatives
15.2.5 Regulations
15.2.6 Regulatory Bodies
15.2.7 Major Associations
15.2.8 Taxes Levied
15.2.9 Corporate Tax Structure
15.2.10 Major Companies
15.3 South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.4 South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.5 South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.6 Brazil Market
15.7 Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.8 Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.9 Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16 Middle East Market
16.1 Summary
16.2 Market Overview
16.2.1 Region Information
16.2.2 Market Information
16.2.3 Background Information
16.2.4 Government Initiatives
16.2.5 Regulations
16.2.6 Regulatory Bodies
16.2.7 Major Associations
16.2.8 Taxes Levied
16.2.9 Corporate Tax Structure
16.2.10 Major Companies
16.3 Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.4 Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.5 Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17 Africa Market
17.1 Summary
17.2 Market Overview
17.2.1 Region Information
17.2.2 Market Information
17.2.3 Background Information
17.2.4 Government Initiatives
17.2.5 Regulations
17.2.6 Regulatory Bodies
17.2.7 Major Associations
17.2.8 Taxes Levied
17.2.9 Corporate Tax Structure
17.2.10 Major Companies
17.3 Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.4 Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.5 Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
